The African Centre for Biodiversity (ACB) has made a submission to the Registrar of GMOs in South Africa, following an application made by Professor Shabir Ahmed Madhi, from the Respiratory and Meningeal Pathogens Research Unit (RMPRU), Chris Hani Baragwanath Academic Hospital, for approval for release of ChAdOx1 nCo-V-19, a genetically modified (GM) vaccine, for clinical phase I/II trials on 2 800 both healthy and HIV-positive adults over a period of 12 months.
Conducted silently and out of the public eye, a three-year experiment involving a new and potentially unsafe and risky genetically modified (GM) fungus to kill mosquitoes was performed in the village of Soumousso in Burkina Faso in 2019. When the study was published in a US scientific journal in May 2019, a media frenzy broke out, heralding the experiments as a breakthrough cure for malaria.
The GM fungus was developed by introducing a toxin from the lethal Australian Blue Mountains funnel-web spider into the M. pingshaense fungus, to ostensibly increase the efficiency of the fungus to kill mosquitoes and stave off malaria.
ACB brings you a new discussion paper
Dear Friends and Colleagues,
Expeditious and affordable access to medicines and other healthcare items will be critical to reducing the toll of COVID-19 in Africa. But if nothing is done to compel corporations to make their patents and trade secrets available to any capable manufacturer so that antivirals, vaccines, and other critical supplies reach Africa in a timely manner, much of the continent could find itself hostage to high prices and the last to receive lifesaving drugs and vaccines.